CARDIAC MARKERS CONFERENCE

8 February 2018

  5.25 CME Points Available

Za’abeel Hall 3, Conference Room 3

Overview

The use of biomarkers in aiding the diagnosis and treatment of cardiac disorders is increasing globally as they offer the opportunity to improve the clinical assessment of coronary diseases while reducing costs. The laboratory plays a critical role in the selection and analysis of such biomarkers highlighting the need for clinicians and the laboratory to work in closer harmony to enhance patient care and improve the quality and reliability of these tests.

This conference will discuss best practices for collaboration between cardiologists and the laboratory in relation to the most recent and prevalent biomarkers. Major analytic and clinical issues will be addressed, along with advice on the most recent regulations surrounding the use of cardiac biomarkers in practice. Cardiovascular and laboratory professionals will not only be equipped with world-class knowledge helping to improve patient care, but partake in networking with thousands of medical laboratory and clinical specialists.

This is the only focused cardiac marker interpretation conference in the region led by clinicians and laboratory professionals which will discuss about developments in current and new markers for acute coronary syndrome, atherosclerosis, chronic heart failure and non-cardiac conditions. 

What are the main topics covered in this event?

  • High sensitivity assays
  • Biochemical markers of acute coronary syndrome
  • Biomarkers for atherosclerosis and metabolic syndrome
  • Biomarkers for chronic heart failure
     

Benefits of Attendance

  • Evaluate the role of cardiac markers in acute coronary syndrome and chronic heart failure to reduce cardiovascular related mortality
  • Discuss high sensitivity assays and how to use them to improve the accuracy and reliability of diagnosis and discharge decisions
  • Assess the most recent biomarkers for atherosclerosis and metabolic syndrome to improve the quality of clinical decision making

Activity Director: Dr Fadi W. Abdul –Karim, Professor of Pathology and Vice Chair for Education, Robert Tomsich Pathology and Lab Med Institute, Cleveland Clinic, Cleveland, Ohio, USA

Local Chair: Professor Abdullah Shehab, President Emirates Cardiac Society; Professor of Cardiovascular Medicine, Department of Internal Medicine, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, UAE

Cleveland Clinic Foundation Centre for Continuing Education acknowledges educational grants for partial support of this activity from: Beckman Coulter | Siemens Healthineers

Provided by:

Cleveland Clinic Foundation Centre for Continuing Education acknowledges educational grants for partial support of this activity from: 
Beckman Coulter | Siemens Healthineers

09.50

Opening remarks by the chair:

Prof Abdullah Shehab, President Emirates Cardiac Society; Professor of Cardiovascular Medicine, Department of Internal Medicine, College of Medicine and Health Sciences, UAE University, Al Ain, UAE  

Session 1 - ACUTE CORONARY SYNDROME

Moderator: Prof Abdullah Shehab, President Emirates Cardiac Society; Professor of Cardiovascular Medicine, Department of Internal Medicine, College of Medicine and Health Sciences, UAE University, Al Ain, UAE

10:00

Cardiac markers: Introduction

Dr Omar K Hallak, Consultant, Interventional Cardiology; Chief, Interventional Cardiologist, Heart Center, American Hospital, Dubai, UAE

10:30

High sensitivity assays and how to use them

Dr Paul Collinson, Consultant Chemical Pathologist, St George's University Hospitals NHS Foundation Trust, London, UK

11:00 Coffee Break


Session 2 : CASES AND THE ROLE OF BIOMARKERS

Moderator: Jeff Meeusen, Co-Director of Cardiovascular Laboratory Medicine, Mayo Clinic, Rochester, Minnesota, USA 

11.30

Case studies in acute coronary syndrome and the role of biomarkers

Dr Abdul Majeed Brek Al Zubaidi, Chair of Cardiac Sciences, Sheikh Khalifa Medical City, Abu Dhabi, UAE 

12.00

Panel discussion - The role of biomarkers in acute coronary syndrome cases: laboratory/cardiology interplay

Moderator: Prof Abdullah Shehab, President Emirates Cardiac Society; Professor of Cardiovascular Medicine, Department of Internal Medicine, College of Medicine and Health Sciences, UAE University, Al Ain, UAE 

Panelists:

  • Dr Abdul Majeed Brek Al Zubaidi, Chair of Cardiac Sciences, Sheikh Khalifa Medical City, Abu Dhabi, UAE 
  • Dr Paul Collinson, Consultant Chemical Pathologist, St George's University Hospitals NHS Foundation Trust, London, UK

12.30 Lunch Break


Session 3 - HEART FAILURE AND LIPIDS

Moderator: Dr Paul Collinson, Consultant Chemical Pathologist, St George's University Hospitals NHS Foundation Trust, London, UK  

13.45

Plasma Ceramides: A new class of lipid biomarkers to identify patients at imminent risk for adverse cardiovascular events

Jeff Meeusen, Co-Director of Cardiovascular Laboratory Medicine, Mayo Clinic, Rochester, Minnesota, USA

14.20

Raising the bar: bone derived biomarkers and outcomes management in heart failure

Prof Damien Gruson, Professor, Head of Clinical Chemistry, Cliniques Universitaires Saint-Luc, Brussels, Belgium 

15:00 Coffee Break

15.30

The demise of CK-MB in screening chest pains

Dr Kashif Bin Naeem, Specialist Cardiologist, Al Baraha Hospital, Dubai, UAE

16.00

Biochemical markers of chronic heart failure and risk stratification

Dr Sanjeev K. Agarwal, Consultant Interventional Cardiologist, Rashid Hospital, Dubai, UAE


16:30 End of conference

Supported by:

ACTIVITY DIRECTOR:

Dr Fadi W. Abdul –Karim, Professor of Pathology and Vice Chair for Education, Robert Tomsich Pathology and Lab Med Institute, Cleveland Clinic, Cleveland, Ohio, USA


CO-ACTIVITY DIRECTOR:

Conference Chair: Prof Abdullah Shehab, President Emirates Cardiac Society; Professor of Cardiovascular Medicine, Department of Internal Medicine, College of Medicine and Health Sciences, UAE University, Al Ain, UAE

SPEAKER FACULTY:

Dr Abdul Majeed Brek Al Zubaidi, Chair of Cardiac Sciences, Sheikh Khalifa Medical City, Abu Dhabi, UAE

Prof Damien Gruson, Professor, Head of Clinical Chemistry, Cliniques Universitaires Saint-Luc, Brussels, Belgium 

Jeff Meeusen, Co-Director of Cardiovascular Laboratory Medicine, Mayo Clinic, Rochester, Minnesota, USA 

Dr Kashif Bin Naeem, Specialist Cardiologist, Al Baraha Hospital, Dubai, UAE

Dr Omar K Hallak, Consultant, Interventional Cardiology; Chief, Interventional Cardiologist, Heart Center, American Hospital, Dubai, UAE

Dr Paul Collinson, Consultant Chemical Pathologist, St George's University Hospitals NHS Foundation Trust, London, UK

Dr Sanjeev K. Agarwal, Consultant Interventional Cardiologist, Rashid Hospital, Dubai, UAE  

 

Supported by: